The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
19 Apr 2021
ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021
18 Mar 2021
ADOCIA Announces Financial Results 2020 And Provides Corporate Update.
17 Mar 2021
Number of shares and voting rights of ADOCIA as of February 28th, 2021
10 Mar 2021
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
16 Feb 2021
Number of shares and voting rights of ADOCIA as of January 31, 2021
25 Jan 2021
Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao
20 Jan 2021
Number of shares and voting rights of ADOCIA as of December 31, 2020
18 Jan 2021
Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets
11 Jan 2021
Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes
21 Dec 2020
Adocia announces its financial calendar for 2021
07 Dec 2020
Number of shares and voting rights of ADOCIA as of November 30, 2020
06 Nov 2020
Number of shares and voting rights of ADOCIA as of October 31, 2020
20 Oct 2020
Adocia Announces Third Quarter 2020 Financial Results
09 Oct 2020
Number of shares and voting rights of ADOCIA as of September 30, 2020
22 Sep 2020
Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020
15 Sep 2020
Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes.
10 Sep 2020
ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr. Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
08 Sep 2020
Number of shares and voting rights of ADOCIA as of August 31, 2020
07 Sep 2020
September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event)
05 Sep 2020
ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.
03 Sep 2020
September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD).
25 Aug 2020
Number of shares and voting rights of ADOCIA as of July 31, 2020
18 Aug 2020
Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019.
30 Jul 2020
Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S
20 Jul 2020
Adocia Announces First Half 2020 Financial Results
06 Jul 2020
Number of shares and voting rights of ADOCIA as of June 30, 2020
16 Jun 2020
ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
16 Jun 2020
ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
16 Jun 2020
ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
08 Jun 2020
Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience
05 Jun 2020
Number of shares and voting rights of ADOCIA as of May 31, 2020
03 Jun 2020
ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience.
11 May 2020
Number of shares and voting rights of ADOCIA as of April 30, 2020
23 Apr 2020
Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes
23 Apr 2020
Adocia announces the release of its Universal Reference Document for the year 2019
20 Apr 2020
Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon
14 Apr 2020
Adocia announces first quarter 2020 financial results and update on the impact of COVID-19
09 Apr 2020
Number of shares and voting rights of ADOCIA as of March 31, 2020
12 Mar 2020
Adocia Announces Full Year 2019 Financial Results
05 Mar 2020
Number of shares and voting rights of ADOCIA as of February 28, 2020
21 Feb 2020
“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)
07 Jan 2020
Number of shares and voting rights of ADOCIA as of December 31, 2019
17 Dec 2019
Adocia announces its financial calendar for 2020
11 Dec 2019
Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners
06 Dec 2019
Number of shares and voting rights of ADOCIA as of November 30, 2019
07 Nov 2019
Number of shares and voting rights of ADOCIA as of October 31st, 2019
22 Oct 2019
Adocia Announces Third Quarter 2019 Financial Results
14 Oct 2019
Adocia obtains additional financial resources to accelerate its growth
04 Oct 2019
Number of shares and voting rights of ADOCIA as of September 30, 2019
30 Sep 2019
Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case
Join our mailing list. Subscribe